• PathAI Enters Partnership With Google Cloud, Cardiometabolic Clinical Trials Platform, DNA/RNA Extraction Kits, More

    Clinical Research News | PathAI announced a strategic partnership with Google Cloud at Bio-IT World Conference & Expo to help biopharma companies and anatomic pathology labs accelerate the adoption of AI and digital pathology; Clinical ink has launched GlucoseReady, a fully integrated GCP compliant digital platform designed for the new era of cardiometabolic clinical trials; New England Biolabs has released its Monarch Mag Viral DNA/RNA Extraction Kit, which enhances recovery of low amounts of viral nucleic acid to enable highly sensitive detection; more.

    Apr 25, 2024

  • Follow the Money: Obesity Medicine Company Metsera Launched, Tumor-Infiltrating Lymphocyte Program, Novel Oncology Biologics, More

    Clinical Research News | Metsera has launched and will rapidly advance a broad portfolio of oral and injectable incretin, nonincretin, and combination therapies designed to meet the future needs of a rapidly evolving weight loss treatment landscape; Obsidian Therapeutics plans to advance its lead engineered tumor-infiltrating lymphocyte program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer; TORL BioTherapeutics has publicly launched and plans to advance its pipeline of antibody-drug conjugates and monoclonal antibodies; more.

    Apr 24, 2024

  • We Need a People-First Approach to Clinical Trial Technology

    Clinical Research News | The proliferation of mobile technology—including multiple generations of progressively smarter phones, tablets, watches, and other devices—has set the stage for similar types of eClinical innovation. However, the two types of technologies have not progressed at the same pace. This is unfortunate for all clinical trial stakeholders and, most notably, patients.

    Apr 19, 2024

  • EEG Monitoring Concerningly Underutilized In Clinical Trials

    Clinical Research News | Study sponsors making choices about if, when, and how to include brain monitoring in their clinical studies do not often ground those choices in science or optimize for subject safety and trial de-risking.The key problem is a lack of electroencephalogram (EEG) expertise with no guidance from the Food and Drug Administration (FDA) to mitigate the situation.

    Apr 16, 2024